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Artemisia species are a rich source of herbal remedies with antioxidant and anti-inﬂammatory properties. We evaluated PMI-
5011, an ethanolic extract of Artemisia dracunculus L., on neuropathy in high-sfat diet-fed mice, a model of prediabetes and
obesity developing oxidative stress and proinﬂammatory changes in peripheral nervous system. C57Bl6/J mice fed high-fat diet for
16 weeks developed obesity, moderate nonfasting hyperglycemia, nerve conduction deﬁcit, thermal and mechanical hypoalgesia,
and tactile allodynia. They displayed 12/15-lipoxygenase overexpression, 12(S)-hydroxyeicosatetraenoic acid accumulation, and
nitrosative stress in peripheral nerve and spinal cord. PMI-5011 (500mgkg
−1d
−1, 7 weeks) normalized glycemia, alleviated nerve
conduction slowing and sensory neuropathy, and reduced 12/15-lipoxygenase upregulation and nitrated protein expression in
peripheral nervous system. PMI-5011, a safe and nontoxic botanical extract, may ﬁnd use in treatment of neuropathic changes at
the earliest stage of disease.
1.Introduction
Diabetic distal symmetric sensorimotor polyneuropathy
aﬀects ∼50% of patients with diabetes mellitus and is a
leading cause of foot amputation [1]. Evidence for the
development of neuropathic changes at the prediabetic stage,
prior to development of overt hyperglycemia and diabetes
mellitus, is emerging from both clinical [2–4]a n de x p e r i -
mental [5–7] studies. Except the aldose reductase inhibitor
epalrestat in Japan and α-lipoic acid in several countries,
no pathogenetic treatment for diabetic or prediabetic neu-
ropathy is currently available. A number of pharmacological
agents that showed promise in animal studies have been
withdrawn from clinical trials because of a lack of eﬃcacy
or adverse side-eﬀects [8, 9]. The development of nonphar-
macological approaches and, among them, complementary
and alternative medicines for prevention and treatment of
diabetes and prediabetes-associated neuropathic changes is,
therefore, highly warranted.
The plant genus Artemisia, that includes over 1500
species, has been a rich source of herbal remedies in many
countries [10, 11]. Several Artemisia species lower blood
glucose concentrations and have been used for treatment of
diabetes [12, 13]. Fluid extracts of Artemisia plant species
have been reported to reduce oxidative stress associated
with obesity [14] and to display anti-inﬂammatory and
antinociceptive properties [15]. PMI-5011 [16, 17], an
ethanolic extract of Artemisia dracunculus L. with a good
safetyproﬁle[16],hasbeenfoundtoinhibitactivityofaldose
reductase [18], the ﬁrst enzyme of the sorbitol pathway,
known to play an important role in the pathogenesis of both
diabetic and prediabetic neuropathy [6, 19–23].
We previously demonstrated that a high-fat diet (HFD)-
fed mouse with alimentary obesity, hyperinsulinemia, and
impairedglucosetolerancedevelopsnerveconductionveloc-
ity deﬁcit and small sensory ﬁber neuropathy and displays
increased sorbitol pathway activity, oxidative-nitrosative
stress, and pro-inﬂammatory changes in PNS. This mouse,2 Mediators of Inﬂammation
therefore, represents an ideal model for evaluating PMI-
5011 on functional and biochemical manifestations of pre-
diabetic neuropathy. The ﬁndings reported herein provide
evidence of alleviation of HFD-induced nerve conduction
slowingandsmallsensorynerveﬁberdysfunctionafterPMI-
5011 treatment, potentially due to inhibition of oxidative-
nitrosative stress and pro-inﬂammatory response in the
peripheral nervous system (PNS).
2. Methods
2.1. Reagents. Unless otherwise stated, all chemicals were
of reagent-grade quality, and were purchased from Sigma
Chemical Co., St. Louis, MO. PMI-5011, an ethanolic extract
of Artemisia dracunculus L., was prepared and analyzed as
described previously [17]. Ethanol was completely removed
after extraction by heating in a rotavapor. Rabbit poly-
clonal (clone H-100) anti-12-lipoxygenase (LO) antibody
was obtained from Santa Cruz Biotechnology, Santa Cruz,
CA. Mouse monoclonal (clone 1A6) anti-nitrotyrosine (NT)
antibody was purchased from Millipore, Billerica, MA.
2.2. Animals. The experiments were performed in accor-
dance with regulations speciﬁed by the Guide for the Care
and Handling of Laboratory Animals (NIH Publication No.
85-23)andPenningtonBiomedicalResearchCenterProtocol
for Animal Studies. Male C57Bl6/J mice, body weight
∼23–25g, were fed standard mouse chow (PMI Nutrition
International, Brentwood, MO, USA) and had ad libitum
accesstowater.Aftercompletionofbodyweight,non-fasting
blood glucose and peripheral nerve function evaluation,
the mice were randomly assigned to receive normal chow
(NC) or HFD (D12328, 10.5kcal% fat, and D 12330,
58kcal%fatwithcornstarch,resp.,ResearchDiets,Inc.,New
Brunswick, NJ), for 16 weeks (n = 33 per condition). Then
body weights, non-fasting blood glucose concentrations, and
variables of peripheral nerve function have been recorded
again, and NC- and HFD-fed mice have randomly been
divided into three matching in body weights and blood
glucose concentrations subgroups. One subgroup has been
euthanized for tissue harvest (n = 10 per condition). Two
other subgroups of NC- and HFD-fed mice were maintained
with (n = 13) or without (n = 10) treatment with
PMI-5011 (500mgkg
−1d
−1 in 2% Twin 80, 50μLkg−1,b y
oral gavage), for another 7 weeks. After ﬁnal body weight,
blood glucose and peripheral nerve function measurements,
all the mice have been euthanized. Throughout the study,
non-fasting blood glucose measurements were performed
from 9 till 11 am. Physiological and behavioral tests of
peripheral nerve function have been done in the following
order: tactile responses to ﬂexible von Frey ﬁlaments (ﬁrst
day), thermal algesia by tail-ﬂick test (second day), thermal
algesiabypawwithdrawaltest(thirdday),mechanicalalgesia
by Randall-Selitto test (fourth day), and motor (MNCV)
and sensory (SNCV) nerve conduction velocities (ﬁfth day).
Measurements of MNCV and SNCV were taken in mice
anaesthetized with a mixture of ketamine and xylazine
(45mgkg
−1 body weight and 15mgkg
−1 body weight, resp.,
i.p.).
2.3. Anesthesia, Euthanasia, and Tissue Sampling. The ani-
mals were sedated by CO2, and immediately sacriﬁced
by cervical dislocation. Sciatic nerves and spinal cords
were rapidly dissected and frozen in liquid nitrogen for
subsequent assessment of LO and nitrated protein expres-
sion and 12(S)hydroxyeicosatetraenoic acid [12(S)HETE]
concentrations. The biochemical measurements have been
performed before and after PMI-5011 treatment.
2.4. Speciﬁc Methods
2.4.1. Physiological Tests. Sciatic MNCV and hind-limb
digital SNCV have been measured as we have described
elsewhere [24]. TCAT-2 Temperature Controller with RET-
3 Temperature probe and HL-1, Heat Lamp (Physitemp
Instruments, Inc., Clifton, NJ) was used to maintain body
and hind-limb temperature at 37
◦C.
2.4.2. Behavioral Tests
(1) Tactile Responses. Tactile responses were evaluated by
quantifying the withdrawal threshold of the hindpaw in
response to stimulation with ﬂexible von Frey ﬁlaments.
Mice were placed in individual plexiglass boxes on stainless
steel mesh ﬂoor and were allowed to adjust for at least 20
minutes. A series of calibrated von Frey ﬁlaments (IITC Life
Science,WoodlandHills,CA)wasappliedperpendicularlyto
the plantar surface of a hindpaw with suﬃcient force to bend
the ﬁlament for 6s. Typically, 6–8 mice were stimulated one
afteranother,inthesameorder,duringonetestingprocedure
(∼2-3h), and stimulations were repeated 5-6 times. Brisk
withdrawal or paw ﬂinching was considered as a positive
response. In the absence of a response in 50% or more paw
stimulations, a ﬁlament of next greater force was applied.
Stimulation was stopped at the ﬁlament producing a positive
responsein4outof5or6stimulations.Theaveragevaluefor
bucklingweightsofthelastandpreviousﬁlaments(orweight
of the last ﬁlament if the previous one(s) did not produce
any responses) was considered a tactile response threshold,
and was recorded for each paw. For example, if the buckling
weightofthelastﬁlamentproducing4positiveresponseswas
1.5g, and stimulation with two previous ﬁlaments produced
two positive responses to the 1.2g ﬁlament and one positive
response to the 1.0g ﬁlament, then the tactile threshold
would be [(1.5 ×4)+(1.2 ×2)+1.0]/7 = 1.34g. The means
value was taken for statistical analysis.
(2) Thermal Algesia
(a) Plantar (Hargreaves) Test. To determine the sensitivity to
noxious heat, mice were placed within a plexiglass chamber
on a transparent glass surface and allowed to acclimate for at
least 20 minutes. A thermal stimulation meter (IITC model
336 TG Combination Tail Flick and Paw algesia meter, IITC
Life Science, Woodland Hills, CA) was used. The device
was activated after placing the stimulator directly beneath
the plantar surface of the hindpaw. The paw withdrawal
latency in response to the radiant heat (15% intensity which
produced a heating rate of ∼1.3
◦C pers, cut-oﬀ time 30s)Mediators of Inﬂammation 3
was recorded. Floor temperature was set at ∼32-33
◦C( m a n -
ufacturer’s setup). Individual measurements were repeated
four to ﬁve times and the mean value calculated.
(b) Tail-Flick Test. For assessment of tail ﬂick response
latencies, the tail-ﬂick and paw algesia meter described above
was set at 40% heating intensity (heating rate ∼2.5
◦Cp e rs )
with a cut-oﬀ at 10s. Four to ﬁve readings per animal were
taken at 15-minute interval, and the average was calculated.
Mechanical Algesia. Tail pressure thresholds were registered
with the Paw/Tail Pressure Analgesia meter for the Randall-
Selitto test (37215 - Analgesy-Meter, UGO-Basile, Comerio
VA, Italy). Pressure increasing at a linear rate of 10g with
the cut-oﬀ of 250g to avoid tissue injury was applied to the
base of the tail. The applied tail pressure that evoked biting
or licking behavior was registered by analgesia meter and
expressed in g. Three tests separated by at least 15 minutes
were performed for each animal, and the mean value of these
tests was calculated.
2.4.3. Biochemical Studies
(1) Western Blot Analysis of LO and Nitrated Protein Expres-
sions. To assess LO and nitrated protein expressions by
Western blot analysis, sciatic nerve and spinal cord materials
(∼20mg) were placed on ice in 200μLo fR I P Ab u ﬀer
containing 50mmol/l Tris-HCl, pH 7.2; 150mmol/l NaCl;
0.1% sodium dodecyl sulfate; 1% NP-40; 5mmol/l EDTA;
1mmol/l EGTA; 1% sodium deoxycholate and the pro-
tease/phosphataseinhibitorsleupeptin(10μg/mL),pepstatin
(1μg/mL), aprotinin (20μg/mL), benzamidine (10mM),
phenylmethylsulfonyl ﬂuoride (1mM), sodium orthovana-
date (1mmol/l), and homogenized on ice. The homogenates
were sonicated (4 × 10s) and centrifuged at 14,000g for
20 minutes. All the aforementioned steps were performed
at 4◦C. The lysates (20 and 40μg protein for sciatic nerve
and spinal cord, resp.) were mixed with equal volumes of
2× sample-loading buﬀer containing 62.5mmol/l Tris-HCl,
pH 6.8; 2% sodium dodecyl sulfate; 5% β-mercaptoethanol;
10% glycerol and 0.025% bromophenol blue, and frac-
tionated in 10% (nitrated proteins) or 7.5% (LO) sodium
dodecyl sulfate polyacrylamide gel in an electrophoresis cell
(Mini-Protean III; Bio-Rad Laboratories, Richmond, CA).
Electrophoresiswasconductedat15mAconstantcurrentfor
stacking, and at 25mA for protein separation. Gel contents
were electrotransferred (80V, 2h) to nitrocellulose mem-
branes using Mini Trans-Blot cell (Bio-Rad Laboratories,
Richmond, CA) and western transfer buﬀer (25mmol/l Tris-
HCl, pH 8.3; 192mmol/l glycine; and 20% (v/v) methanol)
[19]. Free binding sites were blocked in 2% and 5% (w/v)
bovine serum albumin (for nitrated proteins and LO, resp.)
in 20mmol/l Tris-HCl buﬀer, pH 7.5, containing 150mmol/l
NaCl and 0.05% Tween 20, for 1h, after which LO or
nitrotyrosine antibodies were applied for 2h, for detection
of nitrated protein and LO expressions. The horseradish
peroxidase-conjugated secondary antibody was then applied
for 1h. After extensive washing, protein bands detected
by the antibodies were visualized with the Amersham
ECL Western Blotting Detection Reagent (Little Chalfont,
Buckinghamshire, UK). Membranes were then stripped in
the 25mmol/l glycine-HCl, pH 2.5 buﬀer containing 2%
SDS, and reprobed with β-actin antibody to conﬁrm equal
protein loading.
(2)12(S)HETEMeasurements. Forassessmentof12(S)HET-
E, sciatic nerve and spinal cord samples were homogenized
on ice in 15mM Tris-HCI buﬀer (1:100w/v) containing
140mM NaCl, pH 7.6. Homogenates were centrifuged
at 14,000g (4◦C, 20 minutes). 12(S)HETE concentrations
were measured with the 12(S)-hydroxyeicosatetraenoic acid
Enzyme Immuno Assay kit (Assay Designs, Ann Arbor, MI),
in accordance with the manufacturer’s instructions.
2.5. Statistical Analysis. The results are expressed as Mean ±
SEM. Data were subjected to equality of variance F test
and then to log transformation, if necessary, before one-
way analysis of variance. Where overall signiﬁcance (P<
.05) was attained, individual between-group comparisons
for multiple groups were made using the Student-Newman-
Keuls multiple range test. When between-group variance
diﬀerences could not be normalized by log transformation
(datasets for body weights and plasma glucose), the data
were analyzed by the nonparametric Kruskal-Wallis one-way
analysis of variance, followed by the Bonferroni/Dunn test
for multiple comparisons. Individual pair-wise comparisons
between the groups fed NC and HFD (16-wk time point)
and between the corresponding groups before (16-wk time
point) and after (23-wk time point) PMI-5011 treatment
were made using the unpaired or paired two-tailed Student’s
t-test or Mann-Whitney rank sum test where appropriate.
Signiﬁcance was deﬁned at P ≤ .05.
3. Results
A 16-week HFD feeding resulted in 40% diﬀerence in body
weights between HFD-fed mice and those fed NC (Table 1).
Similar (39%) diﬀerences between the two groups main-
tained at the end of the study. A 7-week PMI-5011 treatment
didnotaﬀectbodyweightsineitherNC-orHFD-fedmice.A
16-week HFD feeding resulted in a modest (14.5%) increase
in non-fasting blood glucose concentrations compared with
the mice fed NC. The diﬀerence between the two groups
was 17% at end of the study. PMI-5011 reduced non-fasting
blood glucose concentration in HFD-fed mice by 8.9%,
compared with the baseline level (16-wk time point) in the
same group (P<. 05), without aﬀecting hyperglycemia in
the NC-fed group.
HFD-fed mice displayed clearly manifest MNCV and
SNCVdeﬁcitsatboth16-and23-weektimepointscompared
with the mice fed NC (Table 2). Note that both MNCV and
SNCV were similar in NC-fed mice at the beginning of the
study and at the 16-wk time point which indicates that HFD
feeding-induced nerve conduction slowing did not develop
due to aﬀected peripheral nerve growth and maturation.
PMI-5011 treatment essentially normalized MNCV and4 Mediators of Inﬂammation
Table 1: Body weights and non-fasting blood glucose concentrations in normal chow and high fat diet-fed mice maintained with and
without PMI-5011 treatment.
Variable Body weight, g Blood glucose, mmol l−1
Group Before T (16-wk time point) After T (23-wk time point) Before T (16-wk time point) After T (23-wk time point)
NC 37.5 ±0.57 36.8 ±0.74 7.50 ±0.19 7.67 ±0.25
NC +T 36.9 ±0.80 36.3 ±0.74 7.28 ±0.18 7.82 ±0.31
HFD 52.6 ±0.36
∗∗ 51.3 ±0.57∗∗ 8.58 ±0.22∗∗ 8.95 ±0.50∗∗
HFD+ T 53.7 ±0.53
∗∗ 50.8 ±0.90∗∗ 8.59 ±0.19∗∗ 7.82 ±0.33
§,##
Data are expressed as Mean ± SEM, n = 10–33 per group. NC: normal chow; T: treatment; HFD: high fat diet; ∗,∗∗P<. 05 and <. 01 versus mice fed NC;
§P<. 05 versus the baseline value (16-wk time point); ##P<. 01 versus untreated mice fed HFD (23-wk time point).
reduced SNCV deﬁcit (to 6% versus 14% at baseline) in
HFD-fed mice. PMI-5011 did not aﬀect either MNCV or
SNCV in the NC-fed group.
Both 16- and 23-week HFD feedings resulted in a
clearlymanifestthermalhypoalgesiadetectedbybothplantar
and tail-ﬂick tests (Table 3). Paw withdrawal and tail-ﬂick
responselatencieswere59%and86%higher(a16-weektime
point) and 73% and 78% higher (a 23-week time point)
in HFD-fed mice compared with the corresponding NC-fed
groups. PMI-5011 treatment alleviated thermal hypoalgesia
in HFD-fed mice, without aﬀecting paw withdrawal or
tail-ﬂick response latencies in the NC-fed group. Another
sensory abnormality developing in HFD-fed mice was tactile
allodynia. Tactile withdrawal thresholds in response to light
touch with ﬂexible von Frey ﬁlaments were reduced by
38% and 50% after HFD feeding for 16 and 23 weeks,
respectively. PMI-5011 treatment alleviated, although did
not completely correct, tactile allodynia in HFD-fed mice,
without increasing tactile response thresholds in the NC-fed
group. Mechanical withdrawal thresholds were 25% higher
(a 16-week time point) and 35% higher (a 23-week time
point) in HFD-fed mice compared with the corresponding
NC-fed groups, consistent with the development of mechan-
ical hypoalgesia. PMI-5011 treatment alleviated mechanical
hypoalgesia in HFD-fed mice, without aﬀecting mechanical
withdrawal thresholds in the NC-fed group.
Sciatic nerve and spinal cord LO expressions were
increased by 32% and 36% (a 16-week time point) and
31% and 29% (a 23-week time point) in HFD-fed mice
compared with those fed NC (Figure 1). PMI-5011 did not
aﬀect LO expression in either tissue in the NC-fed mice.
The extract tended to reduce LO expression in sciatic nerve
and spinal cord of HFD-fed mice, but the diﬀerences with
the corresponding baseline values did not achieve statistical
signiﬁcance.
Sciaticnerveandspinalcord12(S)-HETEconcentrations
were increased by 176% and 136% (a 16-week time point)
and 122% and 126% (a 23-week time point) in HFD-
fed mice compared with the corresponding groups fed NC
(Figure 2). PMI-5011 did not aﬀect 12(S)-HETE concentra-
tions in either tissue in the NC-fed mice, but reduced (sciatic
nerve) and essentially normalized (spinal cord) this variable
in HFD-fed mice.
Sciatic nerve and spinal cord nitrated protein expressions
were increased by 32% and 40% (a 16-week time point)
and 36% and 35% (a 23-week time point) in HFD-fed mice
compared with the corresponding groups fed NC (Figure 3).
PMI-5011 decreased spinal cord nitrated protein accumu-
lation by 29%, and tended to reduce this variable in sciatic
nerve although the diﬀerence with the baseline value was not
of statistical signiﬁcance. Statistically signiﬁcant diﬀerences
in both sciatic nerve and spinal cord nitrated protein levels
were observed between HFD-fed groups maintained with
and without PM-5011 treatment at the end of the study. The
extract did not aﬀect nitrated protein expression in either
tissue in NC-fed mice.
4. Discussion
Peripheral neuropathy in human subjects with diabetes mel-
litus is typically characterized by motor and sensory nerve
conduction slowing and increased vibration and thermal
perception thresholds [1]. A higher prevalence of periph-
eral neuropathy and, predominantly, small sensory ﬁber
neuropathy has been reported in subjects with metabolic
syndrome, a condition that often includes prediabetes and
obesity, and impaired glucose tolerance [2–4]. The present
study provides evidence of the therapeutic eﬃcacy of an
ethanolic extract of Artemisia dracunculus L. on MNCV
and SNCV deﬁcits, thermal and mechanical hypoalgesia,
and tactile allodynia in the model of peripheral neuropathy
associated with prediabetes and alimentary obesity. The
beneﬁcial eﬀects of PMI-5011 may at least partially be
related to inhibition of oxidative-nitrosative stress and LO
upregulation in peripheral nerve and spinal cord. Also
note, that whereas the aforementioned ﬁndings have been
obtained in peripheral nerve in toto, it is plausible that
PMI-5011 inhibits both mechanisms in vasa nervorum.
Endothelial cells contain LO and accumulate 12(S)HETE in
response to high glucose [25, 26]. Both oxidative-stress [27,
28] and increased LO activity [25, 26] have been implicated
in endothelial dysfunction, an important factor in MNCV
and SNCV deﬁcits associated with both diabetic [19, 20, 22,
24, 27–29] and prediabetic [5]n e u r o p a t h y .
Previous extensive studies in animal models revealed that
MNCV and SNCV deﬁcits and small sensory nerve ﬁber
dysfunction are also amenable to treatment with numerous
pharmacological agents. Electrophysiology remains a “gold
standard” approach toward the diagnosis of peripheral
diabetic neuropathy [1] ,a n dM N C Va n dS N C Vh a v eb e e n
assessed in the vast majority of experimental studies of
potential new therapeutics as well as in all major clinicalMediators of Inﬂammation 5
Table 2: Motor and sensory nerve conduction velocities in normal chow and high fat diet-fed mice maintained with and without PMI-5011
treatment.
Groups NC NC +T HFD HFD+ T
Variables
Baseline (prior to the beginning of HFD feeding)
MNCV, ms−1 50.8 ±0.75
SNCV, ms−1 38.4 ±0.71
16-wk time point (prior to PMI-5011 treatment)
MNCV, ms−1 51.8 ±0.87 46.3 ±0.77∗∗
SNCV, ms−1 39.1 ±0.65 33.8 ±0.81∗∗
23-wk time point (ﬁnal measurements)
MNCV, ms−1 51.4 ±1.78 52.3 ±2.14 45.9 ±1.18∗ 51.0 ±1.45§,#
SNCV, ms−1 38.7 ±0.92 37.3 ±1.08 33.6 ±1.14∗∗ 36.8 ±0.92§,£,#
Data are expressed as Mean ± SEM, n = 10–12 per group. NC: normal chow; T: treatment; HFD: high fat diet; MNCV: motor nerve conduction velocity;
SNCV: sensory nerve conduction velocity. ∗,∗∗P<. 05 and <. 01 versus mice fed NC; §P<. 05 versus the baseline value (16-wk time point); £P<. 05 versus
mice fed NC (16-wk time point); #P<. 05 versus untreated mice fed HFD (23-wk time point).
Table 3: Variables of small sensory ﬁber neuropathy in normal chow and high fat diet-fed mice maintained with and without PMI-5011
treatment.
Groups NC NC +T HFD HFD+ T
Variables
Baseline (prior to the beginning of HFD feeding)
Paw withdrawal latency, s−1 8.8 ±0.15
Tail ﬂick response latency, s−1 2.41 ±0.08
Tactile withdrawal threshold, g 1.76 ±0.12
Mechanical withdrawal threshold, g 11.5 ±0.31
16-wk time point (prior to PMI-5011 treatment)
Paw withdrawal latency, s−1 8.2 ±0.17 13.0 ±0.31∗∗
Tail ﬂick response latency, s−1 2.48 ±0.09 4.62 ±0.13∗∗
Tactile withdrawal threshold, g 1.72 ±0.13 1.06 ±0.09∗∗
Mechanical withdrawal threshold, g 10.6 ±0.28 13.3 ±0.24∗∗
23-wk time point (ﬁnal measurements)
Paw withdrawal latency, s−1 9.1 ±0.32 10.3 ±0.41 15.7 ±1.14∗∗ 11.4 ±0.68§,∗,##
Tail ﬂick response latency, s−1 2.29 ±0.11 2.52 ±0.10 4.07 ±0.15∗∗ 2.59 ±0.10§§,##
Tactile withdrawal threshold, g 1.52 ±0.21 1.45 ±0.16 0.76 ±0.03∗∗ 1.20 ±0.08££,#
Mechanical withdrawal threshold, g 11.2 ±0.46 11.2 ±0.36 15.2 ±0.10∗∗ 12.3 ±0.59£,##
Data are expressed as Mean ± SEM, n = 10–12 per group. NC: normal chow; T: treatment; HFD: high fat diet; ∗,∗∗P<. 05 and <. 01 versus corresponding
controls; §,§§P<. 05 and <. 01 versus the baseline value (16-wk time point); £,££P<. 05 and <. 01 versus mice fed NC (16-wk time point); #,##P<. 05 and
<. 01 versus untreated mice fed HFD (23-wk time point).
neuropathy trials [30–35]. Note that whereas experimen-
tal studies demonstrated a complete reversal of diabetes-
induced MNCV and SNCV deﬁcits by a variety of pharma-
cological agents (reviewed in [36, 37]), the results of clinical
trials for example, those of aldose reductase and protein
kinase C inhibitors, were quite modest [30, 31, 34, 35]. Such
modest eﬃcacy was most likely related to insuﬃcient dosage,
with test doses in clinical trials at least one order of mag-
nitude lower than in the corresponding animal studies, and
the use of higher doses was not possible in humans because
o fa d v e r s es i d ee ﬀects. Liver toxicity was a major cause of
withdrawal of several aldose reductase inhibitors [38]. A
signiﬁcant proportion of patients in the recent 6-month
study of the protein kinase C inhibitor ruboxistaurin dis-
played treatment-emergent adverse events [39]. Therefore,
undoubtedly, the development of nonpharmacological and,
in particular, complementary and alternative medicinal ther-
apies for correction of diabetes-associated nerve conduction
velocity deﬁcits is of great importance. In the present study,
the botanical extract PMI-5011 essentially reversed MNCV
and SNCV deﬁcits associated with prediabetic neuropathy.
It also reduced thermal and mechanical hypoalgesia, that
is, sensory loss, which is a major cause of foot ulceration
and amputation in human subjects with diabetes mellitus
[1]. Several herbal extracts and other products have been
reported to alleviate diabetic neuropathic pain and sensory6 Mediators of Inﬂammation
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Figure 1: Representative Western blot analyses ((a), (c), (e), (g)) and content (densitometry, ((b), (d), (f), (h))) of mouse sciatic nerve
((a)–(d)) and spinal cord ((e)–(h)) 12/15-lipoxygenase expressions after 16-week ((a), (b) and (e), (f)) and 23-week ((c), (d) and (g), (h))
feedings with normal chow or high-fat diet with or without PMI-5011. NC: normal chow, HF: high fat diet, T: treatment. Mean ± SEM,
n = 7-8 per group. ∗,∗∗P<. 05 and <. 01 versus mice fed NC.
loss in diabetic rats and mice [40, 41]. However, to our
knowledge, only primrose oil reversed MNCV and SNCV
d e ﬁcitsase ﬀectively[42] asit wasobserved inour studywith
PMI-5011.
As one can see from Table 2, PMI-5011 displayed minor
hypoglycemic activity when administered to HFD-fed mice.
However, it is highly unlikely that small (∼12%–17%)
diﬀerences in blood glucose concentrations were responsible
for signiﬁcant diﬀerences in nerve conduction velocities and
variables of sensory neuropathy among NC-fed, HFD-fed,
and PMI-5011-treated HFD-fed groups. This conclusion is
in line with our previous observations in HFD-fed female
mice which displayed neuropathic changes at the stage of
impaired glucose tolerance, prior to development of overt
hyperglycemia [6]. It is also in agreement with our recent
studiesinSTZ-diabeticmousemodelinwhichPMI-5011did
not aﬀect hyperglycemia, but, nevertheless, alleviated func-
tional manifestations of peripheral neuropathy (P. Watcho,
R. Stavniichuk, I. G. Obrosova, unpubished).
Evidence for the importance of oxidative-nitrosative
stress in peripheral diabetic neuropathy is emerging, and
several antioxidants [27, 28, 43–46], including peroxynitrite
decomposition catalysts [44–46], have been found to coun-
teract MNCV and SNCV deﬁcits and small sensory nerve
ﬁber dysfunction. HFD-fed mice display clearly manifest
nitrosativestressinPNS[6],andthepresentstudy,andPMI-
5011 essentially normalized nitrated protein content in both
peripheralnerveandspinalcord.Therefore,beneﬁcialeﬀects
ofPMI-5011onprediabetic neuropathymayatleastpartially
be explained by antioxidant properties of the extract.
Oxidative stress is closely linked to upregulation of
12/15-LO, an enzyme converting arachidonic acid to 12(S)-
HETE, 15(S)-HETE, and a number of derivatives of these
acids. These lipid-like compounds undergo spontaneous
lipid peroxidation, which leads to induction of oxidative-
nitrosative stress, activation of mitogen-activated protein
kinases (MAPKs), and proinﬂammatory response [25, 26].
MAPK activation has been demonstrated to play an impor-
tant role in peripheral diabetic neuropathy [47, 48]; fur-
thermore, this phenomenon has been identiﬁed in human
diabetic nerve [47]. Evidence for the importance of low-
grade inﬂammation in diabetic neuropathy is also emerging
from both experimental and clinical studies [49–53]. In a
recent study, LO gene deﬁciency prevented western diet-
induced increase in macrophage numbers and monocyte
chemoattractant protein-1 overexpression in mouse visceral
fat [54], thus directly implicating LO in HFD-induced
inﬂammation. As we demonstrated previously [6] and in
the current study, 12/15-lipoxygenase protein overexpres-
sion and activation are present in PNS at the prediabeticMediators of Inﬂammation 7
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Figure 2: 12(S)-hydroxyeicosatetraenoic acid concentrations in sciatic nerve ((a), (b)) and spinal cord ((c), (d)) after 16-week ((a) and (c))
and 23-week ((b) and (d)) feedings with normal chow or high-fat diet with or without PMI-5011. NC: normal chow, HF: high fat diet, T:
treatment. Mean ± SEM, n = 9–13 per group. ∗∗P<. 01 versus mice fed NC; §,§§P<. 05 and <. 01 versus the baseline value (16-wk time
point); £P<. 05 versus mice fed NC (16-wk time point); #,##P<. 05 and <. 01 versus untreated mice fed HFD (23-wk time point).
stage, prior to development of overt hyperglycemia. PMI-
5011 treatment tended to inhibit HFD-induced 12/15-
lipoxygenase overexpression in sciatic nerve, and signiﬁ-
cantly reduced 12(S)-HETE concentrations in both periph-
eral nerve and spinal cord. Thus, PMI-5011 may aﬀect
multiple mechanisms implicated in prediabetic neuropathic
changes by inhibiting LO upregulation. It may also exert
beneﬁcial eﬀect due to aldose reductase inhibiting properties
[18]. Increased aldose reductase activity in tissue-sites for
diabetic complications, including diabetic peripheral nerve,
is known to contribute to the formation of advanced glyca-
tion end products, oxidative-nitrosative stress, and protein
kinase C and poly(ADP-ribose) polymerase activations [22,
23, 55–57]. All these mechanisms have been implicated in
thepathogenesisofperipheraldiabeticneuropathy(reviewed
in [37]). In addition, increased AR activity may cause
LO overexpression and activation by promoting activation
of nuclear factor-κB and activator protein-1 as well as
cytosolic Ca++ accumulation (reviewed in [55]), that is, via
upregulation of three factors essentially required for LO gene
expression and activity [25, 26].
In conclusion, the ethanolic extract of Artemisia dracun-
culus L., PMI-5011, alleviates peripheral nerve dysfunction
in neuropathy associated with prediabetes and alimentary8 Mediators of Inﬂammation
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Figure 3: Representative Western blot analyses ((a), (c), (e), (g)) and content (densitometry, ((b), (d), (f), (h))) of mouse sciatic nerve ((a)–
(d)) and spinal cord ((e)–(h)) nitrated protein expressions after 16-week ((a), (b) and (e), (f)) and 23-week ((c), (d) and (g), (h)) feedings
with normal chow or high-fat diet with or without PMI-5011. NC: normal chow, HF: high fat diet, T: treatment. Mean±SEM, n = 7-8 per
group. ∗,∗∗P<. 05 and <. 01 versus mice fed NC; §P<. 05 versus the baseline value (16-wk time point); #,##P<. 05 and <. 01 versus mice
fed HFD.
obesity, potentially, by multiple mechanisms that are likely
to include, but are not limited by, inhibition of oxidative-
nitrosative stress and LO activation. PMI-5011, a safe and
nontoxic product, may ﬁnd use in management of clinical
diabetic neuropathy at the earliest stage of disease. Further
studies are needed to determine whether PMI-5011 treat-
ment is eﬀective against functional and structural deﬁcits of
advanced diabetic neuropathy.
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